Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137.HK) reported its 2025 fiscal year performance, indicating a revenue increase to RMB 18.6 million, attributed to payments received under an intellectual property licensing and technology transfer agreement with Health元 Group [1] Financial Performance - Revenue for the fiscal year ending December 31, 2025, is projected to be RMB 18.6 million, unchanged from the previous fiscal year ending December 31, 2024 [1] - The company reported a net loss of RMB 224 million, a significant reduction of 56.3% year-on-year [1] - The decrease in loss is primarily due to a reduction in fair value losses on equity investments by RMB 125 million and a decrease in impairment losses by RMB 141 million, mostly of a non-operational nature [1] - The reduction in losses was offset by a decrease in other income during the reporting period [1]
腾盛博药-B(02137.HK)2025年度净亏损2.24亿元 同比减少56.3%